Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov;11(11):913-8.

Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal-phase support in in vitro fertilization (IVF): A randomized clinical trial

Saghar Salehpour  1 , Maryam Tamimi  1 , Nasrin Saharkhiz  1
Affiliations

Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal-phase support in in vitro fertilization (IVF): A randomized clinical trial

Saghar Salehpour et al. Iran J Reprod Med. 2013 Nov.

Abstract

Background: Luteal phase support is mandatory in assisted reproductive technologies (ART) for optimizing outcome, so the luteal phase is supported with either progesterone, addition of estradiol to progesterone, hCG or gonadotropin releasing hormone (GnRH) agonists. Supplementation of luteal phase with progesterone is prescribed for women undergoing routine IVF treatment.

Objective: To compare oral dydrogestrone with vaginal progesterone for luteal-phase support in IVF.

Materials and methods: We performed this prospective, randomized trial in a tertiary infertility care unit in Taleghani Hospital, Tehran, Iran. In total 80 Women with a history of male factor infertility undergoing controlled ovarian stimulation for IVF treatment (fresh cycle) randomly were divided in two groups (group A or oral dydrogesterone group and group B or vaginal progesterone group). The inclusion criteria were the use of GnRH analogue down-regulation and age less than 40 years old with regular menstrual cycles. All women were euthyroid and normoprolactinemic. Group A (n=40) received 10 mg dydrogesterone QID (40mg daily) and group B (n=40) received 400 mg suppository vaginal progesterone (cyclogest) twice per day (800 mg daily).

Results: Clinical pregnancy rate in cyclogest group was higher than dydrogesterone group but the difference was not significant (p=0.52), furthermore the miscarriage rate in two group was the same .The difference between two groups regarding antral follicle, embryo number, luteal-phase duration, endometrial thickness, oocyte number and metaphase-II was not significant (p>0.05).

Conclusion: The results showed that oral dydrogesterone is as effective as vaginal progesterone for luteal-phase support in women undergoing IVF.

Keywords: Dydrogesterone; In vitro fertilization; Luteal-phase support; Vaginal progesterone.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Consort flow diagram
See this image and copyright information in PMC

References

    1. Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab . 2003;14:236–242. - PubMed
    1. Devroey P, Bourgain C, Macklon NS, Fauser BC. Reproductive biology and IVF: ovarian stimulation and endometrial receptivity. Trends Endocrinol Metab . 2004;15:84–90. - PubMed
    1. Beckers NGM, Macklon NS, Eijkemans MJC. Comparison of the nonsupplemented luteal phase characteristics after recombinant (r) HCG, rLH or GnRH agonist for oocyte maturation in IVF. Hum Reprod . 2002;17 :55. - PubMed
    1. Penarrubia J, Balasch J, Fábregues F, Creus M, Casamitjana R, Ballescá JL, et al. Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin releasing hormone agonist-induced ovulation in gonadotrophin stimulated cycles. Hum Reprod . 1998;13:3315–3318. - PubMed
    1. Albano C, Grimbizis G, Smitz J, Riethmüller-Winzen H, Reissmann T, Van Steirteghem A, et al. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin releasing hormone antagonist Cetrorelix. Fertil Steril . 1998;70:357–359. - PubMed

LinkOut - more resources